Mode
Text Size
Log in / Sign up
N/A N=37 Treatment

Evaluation of the Ulthera® System for Treatment of the Brachia

Brachial Ptosis

Enrolled (actual)
37
Serious AEs
0.0%
Results posted
May 2014
Primary outcome: Primary: Improvement in Obtaining Lift and Tightening of Brachial Skin Laxity — 48 percentage of participants improved

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Ulthera® System (Device)
Age
Adult · 19+ yrs
Sex
All
Sponsor
Ulthera, Inc
Primary completion
Feb 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Improvement in Obtaining Lift and Tightening of Brachial Skin Laxity
48
SECONDARY
Quantitative Improvement in Skin Laxity
54; 62; 35
SECONDARY
Change in Dermal Thickness
0.099; 0.085
SECONDARY
Change in Dermal Thickness
0.099; 0.085
SECONDARY
Overall Aesthetic Improvement
6.5; 16.1; 48.4; 29; 0; 0
SECONDARY
Overall Aesthetic Improvement
6.5; 16.1; 48.4; 29; 0; 0
SECONDARY
Overall Aesthetic Improvement
6.5; 16.1; 48.4; 29; 0; 0
SECONDARY
Patient Satisfaction
12.9; 64.5; 22.5; 0; 70.9
SECONDARY
Patient Satisfaction
12.9; 64.5; 22.5; 0; 70.9

Summary

This study is an evaluation of the Ulthera® System used to treat the upper arms for improvement of brachial ptosis. All enrolled subjects will receive one bilateral upper arm treatment. Follow-up visits will occur at 60, 90 and 180 days post-treatment.

Eligibility Criteria

Inclusion Criteria

  • Male or female, aged 19 - 55 years.
  • Subject in good health.
  • Subjects who desire lift and tightening of the brachia and improvement in skin laxity.
  • Mild to moderate laxity of the upper arm.
  • Mild to moderate subcutaneous fat of the upper arm.
  • Mild crepiness of the skin of the upper arm.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
  • Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.

Exclusion Criteria

  • Presence of an active systemic or local skin disease that may affect wound healing.
  • Severe solar elastosis.
  • Excessive subcutaneous fat in the upper arm.
  • Excessive skin laxity in the upper arm.
  • Significant scarring in areas to be treated.
  • Significant open wounds or lesions in the treatment areas. 7. Severe or cystic acne in the treatment areas.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01713933). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search